Golgi Neurosciences celebrates Lario Therapeutics being awarded “Company Making a Difference 2023 Preclinical” by the Loulou Foundation

Milan (Italy) – Golgi Neurosciences Srl is glad to announce that its portfolio company Lario Therapeutics Limited, a biopharmaceutical company developing first-in-class precision medicines targeting disease-modifying treatments for severe neurological disorders, has received the “CDLK5 Forum Award for Excellence – Company Making a Difference 2023 Pre-clinical” from the Loulou Foundation at the CDKL5 Forum. The award is in recognition of its development of a validated, precision medicine approach in genetic epilepsies.

For more information, please visit Lario Therapeutics web site or Golgi Neurosciences Linkedin page.